The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

From redness to gradual loss of vision to constant irritation, here are the early warning signs of eye diseases that should ...

As we start the new year, many of us are focusing on diet, exercise, healthy living and our general wellbeing. But did you ...

Health scientists from the University of Virginia have found a previously unknown contributor to harmful blood vessel growth ...

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

PARIS, France I January 14, 2025 I PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

Patients at Government Wenlock Hospital will now have access to cutting-edge ophthalmology diagnostics with the addition of ...